{"id":"NCT04252287","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure","officialTitle":"Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-03-10","primaryCompletion":"2021-11-09","completion":"2021-11-09","firstPosted":"2020-02-05","resultsPosted":"2023-01-12","lastUpdate":"2025-03-30"},"enrollment":476,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure"],"interventions":[{"type":"DRUG","name":"Canagliflozin 100 mg","otherNames":["JNJ-28431754","INVOKANA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).","primaryOutcome":{"measure":"Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":4.9,"sd":1.27},{"arm":"Canagliflozin 100 mg","deltaMin":9.2,"sd":1.27}],"pValues":[{"comp":"OG000 vs OG001","p":"0.016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["38385941","37498273","37040839","35228753","33724883"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":231},"commonTop":[]}}